High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]

Fenghuang Zhan; Bart Barlogie; George Mulligan; John D. Shaughnessy; Barb Bryant

doi:10.1182/blood-2007-10-119321

High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]

Fenghuang Zhan
, Bart Barlogie
, George Mulligan
, John D. Shaughnessy
, Barb Bryant

Research output: Contribution to journal › Letter › peer-review

65 Scopus citations

Original language	English
Pages (from-to)	968-969
Number of pages	2
Journal	Blood
Volume	111
Issue number	2
DOIs	https://doi.org/10.1182/blood-2007-10-119321
State	Published - 15 Jan 2008

Access to Document

10.1182/blood-2007-10-119321

Cite this

Zhan, F., Barlogie, B., Mulligan, G., Shaughnessy, J. D., & Bryant, B. (2008). High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]. Blood, 111(2), 968-969. https://doi.org/10.1182/blood-2007-10-119321

@article{dfb50d72a2844db2807047f0d836182e,

title = "High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]",

author = "Fenghuang Zhan and Bart Barlogie and George Mulligan and Shaughnessy, \{John D.\} and Barb Bryant",

year = "2008",

month = jan,

day = "15",

doi = "10.1182/blood-2007-10-119321",

language = "English",

volume = "111",

pages = "968--969",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "2",

}

Zhan, F, Barlogie, B, Mulligan, G, Shaughnessy, JD & Bryant, B 2008, 'High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]', Blood, vol. 111, no. 2, pp. 968-969. https://doi.org/10.1182/blood-2007-10-119321

High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]. / Zhan, Fenghuang; Barlogie, Bart; Mulligan, George et al.
In: Blood, Vol. 111, No. 2, 15.01.2008, p. 968-969.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - High-risk myeloma

T2 - A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]

AU - Zhan, Fenghuang

AU - Barlogie, Bart

AU - Mulligan, George

AU - Shaughnessy, John D.

AU - Bryant, Barb

PY - 2008/1/15

Y1 - 2008/1/15

UR - https://www.scopus.com/pages/publications/38349088637

U2 - 10.1182/blood-2007-10-119321

DO - 10.1182/blood-2007-10-119321

M3 - Letter

C2 - 18182586

AN - SCOPUS:38349088637

SN - 0006-4971

VL - 111

SP - 968

EP - 969

JO - Blood

JF - Blood

IS - 2

ER -

Zhan F, Barlogie B, Mulligan G, Shaughnessy JD, Bryant B. High-risk myeloma: A gene expression-based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone [7]. Blood. 2008 Jan 15;111(2):968-969. doi: 10.1182/blood-2007-10-119321